Literature DB >> 25787232

Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience.

Lucie Lafay-Cousin1, Taryn Fay-McClymont1, Donna Johnston2, Chris Fryer3, Katrin Scheinemann4, Adam Fleming5, Juliette Hukin3, Laura Janzen6, Sharon Guger6, Douglas Strother1, Donald Mabbott6, Annie Huang7, Eric Bouffet7.   

Abstract

BACKGROUND: Because atypical teratoid rhabdoid tumor(ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long-term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of patients are now long-term survivors. PROCEDURE: Retrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry.
RESULTS: Among 77 patients diagnosed between 1995-2012, 16(22%) were survivors. Formal NP assessments were available in eight patients. Partial information on academic achievement was available on three additional patients. There were four girls and seven boys diagnosed at a median age of 27.5 months. Seven patients underwent complete resection and three had metastatic disease. All but one received sequential high dose chemotherapy. Five patients received intrathecal chemotherapy. Three patients underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9-9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50-119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed patients (median time assessment from diagnosis 2.6 years (1.6-4.7)) had average to high average FSIQ, academic and visual spatial skills, visual, and verbal memory. Five other patients diagnosed earlier and tested at a median time of 4.9 years (3.3-8.3) post-diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range.
CONCLUSION: Overall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ATRT; neurocognitive evaluation; survivor

Mesh:

Year:  2015        PMID: 25787232     DOI: 10.1002/pbc.25441

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Long-term survival following additive radiotherapy in patients with atypical teratoid rhabdoid tumors.

Authors:  Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-06-07       Impact factor: 3.621

2.  Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.

Authors:  Mary Fossey; Haocheng Li; Samina Afzal; Anne-Sophie Carret; David D Eisenstat; Adam Fleming; Juliette Hukin; Cynthia Hawkins; Nada Jabado; Donna Johnston; Tania Brown; Valerie Larouche; Katrin Scheinemann; Douglas Strother; Beverly Wilson; Shayna Zelcer; Annie Huang; Eric Bouffet; Lucie Lafay-Cousin
Journal:  J Neurooncol       Date:  2017-01-19       Impact factor: 4.130

3.  Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors.

Authors:  Lindsey M Hoffman; Elizabeth Anne Richardson; Ben Ho; Ashley Margol; Alyssa Reddy; Lucie Lafay-Cousin; Susan Chi; Irene Slavc; Alexander Judkins; Martin Hasselblatt; Franck Bourdeaut; Michael C Frühwald; Rajeev Vibhakar; Eric Bouffet; Annie Huang
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

4.  An Integrated Analysis of Clinical, Genomic, and Imaging Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer Survivors, Enriched with CNS Tumors (Rad ART Pro).

Authors:  Cassie Kline; Schuyler Stoller; Lennox Byer; David Samuel; Janine M Lupo; Melanie A Morrison; Andreas M Rauschecker; Pierre Nedelec; Walter Faig; Dena B Dubal; Heather J Fullerton; Sabine Mueller
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

5.  Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years.

Authors:  Meerim Park; Jung Woo Han; Seung Min Hahn; Jun Ah Lee; Joo-Young Kim; Sang Hoon Shin; Dong-Seok Kim; Hong In Yoon; Kyung Taek Hong; Jung Yoon Choi; Hyoung Jin Kang; Hee Young Shin; Ji Hoon Phi; Seung-Ki Kim; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Do Hoon Lim; Hyung Jin Shin; Hyery Kim; Kyung-Nam Koh; Ho Joon Im; Seung Do Ahn; Young-Shin Ra; Hee-Jo Baek; Hoon Kook; Tae-Young Jung; Hyoung Soo Choi; Chae-Yong Kim; Hyeon Jin Park; Chuhl Joo Lyu
Journal:  Cancer Res Treat       Date:  2020-10-28       Impact factor: 4.679

6.  Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.

Authors:  Irina Alimova; Dong Wang; Etienne Danis; Angela Pierce; Andrew Donson; Natalie Serkova; Krishna Madhavan; Senthilnath Lakshmanachetty; Ilango Balakrishnan; Nicholas K Foreman; Siddhartha Mitra; Sujatha Venkataraman; Rajeev Vibhakar
Journal:  Int J Oncol       Date:  2022-02-18       Impact factor: 5.650

Review 7.  Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics.

Authors:  Cody L Nesvick; Lucie Lafay-Cousin; Aditya Raghunathan; Eric Bouffet; Annie A Huang; David J Daniels
Journal:  J Neurooncol       Date:  2020-10-06       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.